UPDATE -- CapsoVision, Inc. Announces CE Mark for the Use of CapsoCam Plus Capsule Endoscopy System in Patients Ages 2 and Above*
Award-winning technology provides 360º imaging, eliminates need for receiver equipment during examination
SARATOGA, Calif., Oct. 27, 2017 (GLOBE NEWSWIRE) -- Today Silicon Valley-based CapsoVision, Inc. announced CE Mark approval for their CapsoCam Plus® System in patients ages 2 and above*. It is the only wire-free capsule endoscopy system on the market that provides a full 360° panoramic lateral image of the small bowel mucosa.
"Gastroenterologists and patients have told us that CapsoCam Plus provided them with comfort and convenience compared to other capsule endoscopy systems," CapsoVision President Johnny Wang said. "Since CapsoCam Plus does not require patients to wear a data recorder like with ordinary capsule endoscopes, these benefits are more pronounced for use with younger patients and their caregivers."
The incidence of Inflammatory Bowel Disease (IBD) in pediatric patients worldwide is on the rise, particularly in Europe. According to a recent report commissioned by United European Gastroenterology (UEG), childhood onset of IBD now accounts for 20-30% of all IBD cases.1 Capsule endoscopy is one of the tools that pediatric gastroenterologists use to identify abnormalities of the small bowel that may lead to an IBD diagnosis.
Dr. Salvatore Oliva, pediatric gastroenterologist at the Sapienza University of Rome, Italy, will discuss the use of CapsoCam Plus in patients ages 2 and above at the United European Gastroenterology Week (UEGW) in Barcelona on October 31, 2017 at the CapsoVision exhibit booth and at a Panel Presentation in the evening. More information can be found at CapsoVision.com/events.
* Approved for usage outside of the United States only
About CapsoVision, Inc.
CapsoVision, Inc. is a medical device innovator located in Silicon Valley. A company with out-of-the-box thinking and enviable human capital, CapsoVision strives to empower physicians and patients with innovative technologies that will provide superior clinical outcomes and improve quality of life. CapsoVision is currently working in 70+ countries through strong distribution partners.
The innovations embedded in the CapsoCam Plus system are seen to enhance physician experience in observing and diagnosing small bowel abnormalities while providing unparalleled comfort, convenience, and freedom to patients. CapsoCam's cutting-edge 360° panoramic lateral view and wire-free technology are setting new standards in capsule endoscopy. For more information, visit CapsoVision.com.
1Paediatric Digestive Health Across Europe: Early Nutrition, Liver Disease and Inflammatory Bowel Disease. United European Gastroenterology (UEG) EU Affairs. May 2016. https://www.ueg.eu/epaper/UEG_Paediatric_Digestive_Health_Report/index.html
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: CapsoVision Inc. via Globenewswire
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
GlobeNewswire Test Release16.6.2018 07:00 | Pressemelding
LOS ANGELES, June 15, 2018 (GLOBE NEWSWIRE) -- This is a test from GlobeNewswire. Readers are advised to disregard. TESTING -- TESTING -- TESTING -- TESTING -- TESTING -- TESTING -- TESTING -- TESTING – -END- CONTACT: Karen Yu Director, GlobeNewswire Product Management Direct: +1 310 258 6917 Mobile: +1 626 389 7427 or Magali Rolandez Senior Manager, Media Relations/Content Distribution Europe Direct: +44 (0) 203 753 2215 Mobile: +44 (0) 7785 619 539
INVNT/IP: US Responds to Nation-sponsored Crown-jewel Intellectual Property Theft15.6.2018 23:34 | Pressemelding
US Announcement of Large-Scale Tariffs in Response to Chinese Crown-Jewel Intellectual Property Theft Lauded by IP Protection Consortium INVNT/IP SEATTLE, June 15, 2018 (GLOBE NEWSWIRE) -- The Trump administration today announced 25% tariffs on $50 billion in Chinese goods, representing the first time the United States government has marked sectors in US-China trade for retaliation as a response to theft of crown-jewel intellectual property. In a public statement, President Trump announced that the measures were targeted toward goods that "contain industrially significant technologies." US Trade Representative Robert Lighthizer applauded the move on Fox News, noting, "It's thorough. It's moderate. It's appropriate." In a further explanation of the move, he added, "What I want to do is make sure that we protect our technology here at home, that we stop cybertheft and forced technology transfer, and ultimately, remember: 'China 2025' is a $300 billion subsidy program. The United States h
Brookfield Asset Management Announces Results of Annual and Special Meeting of Shareholders15.6.2018 22:30 | Pressemelding
BROOKFIELD, NEWS, June 15, 2018 (GLOBE NEWSWIRE) -- Brookfield Asset Management Inc. (TSX:BAM.A) (NYSE:BAM) (Euronext:BAMA) today announced that at the company's annual and special meeting of shareholders held earlier today in Toronto, approximately 92% of Class A Limited Voting Shares ("Class A Shares") voted in favour of an advisory vote approving the company's approach to executive compensation. In addition, at the meeting all eight nominees proposed for election to the board of directors by holders of Class A Shares and all eight nominees proposed for election to the board of directors by the holder of Class B Limited Voting Shares ("Class B Shares") were elected. Detailed results of the vote for the election of directors are set out below. Management received the following proxies from holders of Class A Shares in regard to the election of the eight directors nominated by this shareholder class: Director Nominee Votes For % Votes Withheld % M. Elyse Allan 620,669,437 99.53 2,921,9
NEP Completes Acquisition of Telerecord15.6.2018 13:53 | Pressemelding
FLORENCE, Italy, June 15, 2018 (GLOBE NEWSWIRE) -- Today NEP Group, a leading outsourced technical production partner supporting premier content producers of live sports and entertainment, announced that it has completed its acquisition of Telerecord, an Italy-based provider of outside broadcast solutions. Telerecord, a local industry leader with strong client relationships, covers popular sporting events in Italy and throughout Southern Europe including football, ice hockey and bobsleigh. The deal further diversifies NEP's business and expands its reach in Europe by adding additional local resources and talent. As part of the deal, all Telerecord staff members will join NEP. Telerecord will be rebranded as NEP and will be part of NEP Italy, which is led by Sergio Cecchini, GM of NEP Italy, who joined NEP in May. Telerecord also brings a fleet of several outside broadcast trucks, sprinter vans and motorcycles to the NEP Worldwide Network to serve clients across Europe. "We couldn't be
Fortuna Reports Results of Annual General Meeting15.6.2018 11:00 | Pressemelding
VANCOUVER, British Columbia, June 15, 2018 (GLOBE NEWSWIRE) -- Fortuna Silver Mines Inc. (NYSE:FSM) (TSX:FVI) hereby announces the voting results at the Company's annual general meeting held on June 14, 2018. A total of 108,538,241 common shares were represented at the meeting, being 68% of the Company's issued and outstanding shares. Shareholders voted in favour of all matters brought before the meeting including the appointment of auditors, the election of management's nominees as directors, and the ratification and approval of the Company's amended Advance Notice Policy. Detailed results of the votes on the election of directors are as follows: Director Votes For Votes Withheld Jorge Ganoza Durant Simon Ridgway Mario Szotlender David Farrell David Laing Alfredo Sillau Kylie Dickson 74,947,635 (97.4%) 63,448,600 (82.5%) 70,831,225 (92.1%) 74,816,864 (97.3%) 73,597,731 (95.7%) 75,716,342 (98.4%) 76,476,115 (99.4%) 1,930,230 (2.5%) 13,429,266 (17.4%) 6,046,640 (7.9%) 2,061,001 (2.7%) 3
ERYTECH to Present Preclinical and Clinical Data on Use of Eryaspase in ALL and AML at EHA 201815.6.2018 07:31 | Pressemelding
LYON, France, June 15, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext:ERYP) (Nasdaq:ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will present preclinical data on the enzymatic activity of eryaspase (GRASPA®) for the treatment of relapsed acute lymphoblastic leukemia (ALL) and results of its Phase 2b clinical trial evaluating eryaspase (GRASPA®) for the treatment of acute myeloid leukemia (AML) at the European Hematology Association (EHA) Congress, being held June 14-17, 2018 in Stockholm, Sweden. The preclinical eryaspase data will be presented during Poster Session I by Dr. Karine Aguera, ERYTECH's R&D Project Leader. Poster Session: Preclinical Demonstration of Intracellular Activity of Asparaginase Encapsulated in Red Blood Cells Both in the Absence and in the Presence of Neutralizing Anti-Asparaginase Antibodies Abstract #: PF160 Lead Author: Karine A
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom